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OBJECTIVES: Older antiepileptic drugs (AEDs) are known to have a narrow 
therapeutic index. As a consequence, switching between bioequivalent AEDs 
remains controversial in the management of epilepsy. We investigated the 
association between A-rated switching of each class of currently available AED 
medication and emergent treatment for a seizure-related event. METHODS: We 
used a case-control method and claims data from the 2010-2011 Truven Health 
MarketScan® Commercial Claims Database to estimate the risk of seizure 
following a medication switch. Cases and controls with an epilepsy diagnosis 
were identified by emergency/inpatient or outpatient visit claims, respectively. 
Cases and controls (n=8,106) were matched 1:1 by age, seizure diagnosis category 
and seizure medication. The exposure was defined as a switch between A-rated 
AEDs during the 90 days prior to index date. Conditional logistic regression was 
used to estimate the association, adjusting for gender, baseline Deyo-Charlson 
Comorbidity Index (0, 1, 2, or 3+), region (Northeast, Central, South, and West), 
and total AED medications. RESULTS: A switch between A-rated AEDs occurred 
in 1053 (23.2%) cases and 818 (18.0%) matched controls. The unadjusted and 
adjusted odds ratios of a seizure-related event for switching were 1.39 (95% CI: 
1.25-1.54) and 1.22 (95% CI: 1.10-1.37), respectively. The independent risk of an 
event also increased with each category increase in the Charlson score (CCI=1: 
1.60, 95% CI: 1.42-1.81; CCI=2: 1.72, 95% CI: 1.44-2.06; CCI=3+: 3.42, 95% CI: 2.84-
4.11). Older AED medications had infrequent switches compared to newer agents 
and were not associated with events. CONCLUSIONS: We found a modest 
association between AED switching and seizure-related events. Our analysis 
suggests that the behavior of switching alone may lead to seizure-related events 
regardless of the medication. Other disease or environmental characteristics 
may contribute to this association. Until more conclusive evidence is available, 
health care professionals and patients should undertake switching of 
bioequivalent AEDs on an individual basis.  
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OBJECTIVES: Pseudobulbar affect (PBA) is a neurological syndrome characterized 
by disinhibition of emotional expression and can occur following traumatic brain 
injury (TBI). Service members returning from Operation Enduring 
Freedom/Operation Iraqi Freedom (OEF/OIF) have unprecedented risk for mild 
TBI (mTBI), primarily from exposure to blast-related munitions. The prevalence 
of PBA in OEF/OIF veterans with mTBI is unknown. This study will determine the 
prevalence of PBA symptoms in OEF/OIF veterans with mTBI and characterize 
the populations with mTBI and PBA symptoms. METHODS: Participants: Veterans 
receiving health care from the VA in the New England region (VISN-1) who tested 
positive on the VA standard TBI screen, excluding those with a current diagnosis 
of bipolar disorder, schizophrenia or other psychotic disorder. Procedure: TBI-
positive veterans will be mailed the Center for Neurologic Study-Lability Scale 
(CNS-LS) questionnaire, a tool to assess PBA symptoms, supplemented with a 
validation question “Have you ever experienced involuntary episodes of crying 
and/or laughing that were exaggerated or even contrary to how you felt at the 
time?” VA clinical data will be used to characterize the entire study population 
and subset that return the CNS-LS questionnaire. Outcome: Participants will 
screen positive for PBA symptoms with a CNS-LS score ≥ 13 and answering yes to 
the validation question. We will determine the prevalence and 95% confidence 
interval of positive screens in the study population. RESULTS: There were 4,951 
OEF/OIF veterans in Massachusetts who completed the VA TBI screen between 
April 2007 and February 2012, of whom 1,051 (21%) tested positive. We are 
currently identifying our study sample and will have preliminary results at the 
time of the conference. CONCLUSIONS: Ultimately, we propose a more 
comprehensive examination of the nation’s veterans with mTBI to determine the 
overall prevalence of PBA. Identifying individuals who may be at risk for PBA will 
have important social and health care implications.  
 
NEUROLOGICAL DISORDERS – Cost Studies 
 
PND18  
A DESCRIPTIVE ANALYSIS OF DRUG ACQUISITION COSTS TO TREAT MULTIPLE 
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OBJECTIVES: The treatment of MS, relapsing-remitting or secondary-progressive 
forms, is available in the Brazilian public health system (SUS), according to 
guidelines of MoH. Here, we describe the profile of the MoH' financial resources 
applied on the acquisition of drugs to treat MS in 2011 and 2012. METHODS: 
Descriptive analysis of the expenses with drugs to treat MS where the MoH is 
responsible for their acquisition: beta-Interferon, glatiramer and natalizumab. 
The expenses were calculated based on the amount dispensed and acquisition 
prices in 2011 and 2012 (current values; exchange rate: US$ 1 = R$ 2.04), obtained 
from MoH databases. RESULTS: In 2011, the expenses of MoH with the 
acquisition of medicines for MS reached to US$ 144,323,965.92, representing 7.2% 
of its annual resources applied on the acquisition of high-cost medications. Of 
this amount, US$ 112,182,371.80 was destined to the beta-interferon (77.8%), US$ 
30,383,351.47 to the glatiramer (21.2%) and US$ 1,758,242.65 to the natalizumab 
(1.0%). In 2012, these same expenses increased to US$ 184,985,919.97 (a 28.2% 
difference). Of this amount, 78.4% was destined to the beta-interferon, 17.9% to 
the glatiramer and 3.7% to the natalizumab (3.7%). During this period, there was 
a mean price reduction of 13.2% (8.0 to 18.4%) and a mean increase of 38.6% (18.4 
to 110%) in the amount of medicines dispensed. CONCLUSIONS: The drugs used 
in MS have relevant impacts on the MoH’ budget. Thus, strategies to optimize 
resources, as the centralized acquisition of these medicines, which occurs since 
2010, provide systematic price reduction and allow larger availability of 
medicines.  
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OBJECTIVES: Adherence to antiepileptic drugs (AEDs) is imperfect and AEDs of 
long half-life or duration of action (e.g., extended release) might mitigate the 
impact of missed doses. We compared costs and utilization between patients 
treated with long-acting (LA) and short-acting (SA) AED monotherapy. 
METHODS: A retrospective cohort analysis was conducted using claims data 
(OptumInsight). We included adult epilepsy patients (≥1 epilepsy diagnosis in 
2010 and 2011) who used AED monotherapy and were continuously enrolled in 
2011. Patients were excluded if they had <2 AED fills, <9 months of treatment, or 
a treatment gap >60 days. Based on published data and expert opinion, AEDs 
were classified as LA or SA. Pharmacy and medical claims in 2011 were used to 
determine costs and utilization. Claims associated with an epilepsy diagnosis, 
test, or AEDs were considered epilepsy-related. Baseline group differences were 
adjusted using multivariate analyses. RESULTS: The 4058 (49.6%) LA users and 
4122 (50.4%) SA users were mean age: 47.7 versus 45.1 years, female: 47.6% 
versus 57.0%; and had epilepsy-specific comorbidities: 19% versus 25%, 
respectively; all P<0.001. Compared with SA users, LA users had lower mean 
overall costs ($9,757 vs. $12,689) and epilepsy-related costs ($3,539 vs. 5,279) and 
lower rate of overall (8.7% vs. 10.8%) and epilepsy-related hospitalization (5.7% 
vs. 7.5%) (all P<0.01). After adjusting for demographics, usual care physician, and 
comorbidities, mean overall costs were lower by $686 (P=0.137) and mean 
epilepsy-related costs by $894 (P=0.005) in LA users than in SA users. 
CONCLUSIONS: Patients with epilepsy treated with LA AED monotherapy incur a 
lower economic burden than those treated with SA AED monotherapy. This 
study indicates that using AEDs with more extended coverage between doses 
may decrease health care use and lower costs. Future studies should examine 
the impact of duration of action on outcomes in combination therapy and in 
adolescents.  
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OBJECTIVES: Current procedures to assess costs of drugs for use in comparative 
effectiveness studies fail to account for important issues related to pharmacy 
practice such as availability of generic drugs, differing manufacturer  
and package sizes, and clinically equivalent and reasonably interchangeable 
dosages. This work proposes a method aimed at better estimation of drug  
costs that includes a level of uncertainty. METHODS: Using patient drug histories 
and the Micromedex Redbook costs database, we construct an algorithm  
which accurately matches every prescription drug order to the full set of 
therapeutically appropriate National Drug Codes (NDCs) that could be used to fill 
each prescription. The algorithm, calculated on a per unit of ingredient, is 
flexible and can be modified to include more or less inclusive sets of  
possible NDC codes based on various definitions of reasonably interchangeable 
drug formulations. We compare a (i) simple method, using only a single NDC 
code, (ii) complete method that matches every potentially suitable NDC code, 
and (iii) pill rationing to favor exact doses. The complete and pill rationing 
methods introduce uncertainty between what was prescribed and what NDC 
code could be used to fill each prescription. RESULTS: As a concrete example 
using 500mg dose of Cephalexin, our simple method yields an estimated cost of 
$2.74 per dose, our complete method with 556 NDCs yielded mean (sd) $3.61 
(2.40), and pill rationing with 314 NDCs yielded mean (sd) $3.55 (1.73). 
CONCLUSIONS: This method highlights several important issues when assessing 
costs of a drug included in comparative effectiveness studies. It also proposes a 
way to better account for uncertainty when modeling estimated costs and more 
consistency in including individuals using the same drug dosage at the same 
cost.  
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OBJECTIVES: To assess increased all-cause costs incurred by patients 
experiencing various adverse effects (AEs) associated with Parkinson’s disease 
(PD) and its treatments in a large, real-world population. METHODS: A 
retrospective analysis was conducted using the MarketScan database, an 
employer-based source of inpatient, outpatient, and pharmacy claims of >30 
million lives from 2000–2011. Inclusion criteria were: ≥1 PD diagnosis (ICD-9-CM 
332.0) and ≥1 anti-PD treatment claim (levodopa, dopamine agonist, 
anticholinergic, MAOB-inhibitor, COMT-inhibitor, or amantadine) during 2000-
2011. Separate case/control cohort analyses were conducted for each AE 
(dyskinesia, orthostatic hypotension, secondary hypertension, nausea, edema, 
